




Searching News Database: urinary tract infection
HSMN NewsFeed - 17 Dec 2020
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
FDA Approves GSK's BENLYSTA as the First Medicine for Adult Patients with Active Lupus Nephritis in the US
HSMN NewsFeed - 22 Sep 2020
NanoVibronix UroShield(R) Receives U.S. Food and Drug Administration Authorization for Entry into the U.S.
NanoVibronix UroShield(R) Receives U.S. Food and Drug Administration Authorization for Entry into the U.S.
HSMN NewsFeed - 4 May 2020
Enteris BioPharma Appoints Rajiv Khosla, Ph.D., as Chief Executive Officer
Enteris BioPharma Appoints Rajiv Khosla, Ph.D., as Chief Executive Officer
HSMN NewsFeed - 16 Mar 2020
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata
HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
HSMN NewsFeed - 10 Feb 2020
Enteris BioPharma Appoints Gary A. Shangold, MD, as Chief Medical Officer
Enteris BioPharma Appoints Gary A. Shangold, MD, as Chief Medical Officer
HSMN NewsFeed - 18 Nov 2019
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
Allergan(R) Announces First Annual National BOTOX(R) Cosmetic (onabotulinumtoxinA) Day
HSMN NewsFeed - 26 Jun 2019
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
HSMN NewsFeed - 18 Mar 2019
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
HSMN NewsFeed - 23 Oct 2018
BioGX Launches 5 new CE Mark IVD Tests, Expands Sexual Health Panels on the BD MAX(TM)
BioGX Launches 5 new CE Mark IVD Tests, Expands Sexual Health Panels on the BD MAX(TM)
HSMN NewsFeed - 19 Jun 2018
GenomeDx Biosciences and Pathnostics Launch Enhanced Version of Guidance Tests
GenomeDx Biosciences and Pathnostics Launch Enhanced Version of Guidance Tests
HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
HSMN NewsFeed - 22 May 2017
Telemedicine Innovator Lemonaid Health Raises $11 Million in Series A Funding
Telemedicine Innovator Lemonaid Health Raises $11 Million in Series A Funding
HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
HSMN NewsFeed - 9 Feb 2016
Aytu BioScience Announces First Commercial Sales for Company's MiOXSYS(TM) System for Male Infertility
Aytu BioScience Announces First Commercial Sales for Company's MiOXSYS(TM) System for Male Infertility
HSMN NewsFeed - 19 Jan 2016
Akorn Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection
Akorn Launches Buprenorphine/Naloxone Sublingual Tablets and Tobramycin Injection
HSMN NewsFeed - 12 Jan 2016
Aytu BioScience Obtains CE Marking for Company's MiOXSYS(TM) System for Male Infertility
Aytu BioScience Obtains CE Marking for Company's MiOXSYS(TM) System for Male Infertility
HSMN NewsFeed - 20 Oct 2015
ConvaTec Introduces GentleCath(TM) Pro Closed-System Intermittent Catheter and GentleCath(TM) Insertion Kit
ConvaTec Introduces GentleCath(TM) Pro Closed-System Intermittent Catheter and GentleCath(TM) Insertion Kit
HSMN NewsFeed - 12 Jun 2015
FDA Approves Promacta(R) for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
FDA Approves Promacta(R) for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
HSMN NewsFeed - 18 May 2015
Vesiflo Introduces the inFlow Device and Its Companion Patient Monitoring System
Vesiflo Introduces the inFlow Device and Its Companion Patient Monitoring System
HSMN NewsFeed - 5 Mar 2015
Tetraphase Pharmaceuticals Appoints Maria Stahl as Senior Vice President and General Counsel
Tetraphase Pharmaceuticals Appoints Maria Stahl as Senior Vice President and General Counsel
HSMN NewsFeed - 30 Oct 2014
U.S. FDA Approves Once-Daily XIGDUO(TM) XR Tablets for Adults with Type 2 Diabetes
U.S. FDA Approves Once-Daily XIGDUO(TM) XR Tablets for Adults with Type 2 Diabetes
HSMN NewsFeed - 1 Jul 2014
Paratek Appoints Michael Bigham as Chairman and CEO and Promotes Evan Loh to President and CMO
Paratek Appoints Michael Bigham as Chairman and CEO and Promotes Evan Loh to President and CMO
HSMN NewsFeed - 18 Jun 2014
Lakewood-Amedex Raises $5.5 Million In Series C Preferred Stock Financing
Lakewood-Amedex Raises $5.5 Million In Series C Preferred Stock Financing
HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
HSMN NewsFeed - 13 Sep 2013
Alexion's Soliris(R) (eculizumab) Receives Marketing Approval in Japan for All Patients with aHUS
Alexion's Soliris(R) (eculizumab) Receives Marketing Approval in Japan for All Patients with aHUS
HSMN NewsFeed - 6 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
HSMN NewsFeed - 3 Sep 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
HSMN NewsFeed - 14 Aug 2013
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
HSMN NewsFeed - 28 Jun 2013
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
Genzyme Receives Positive CHMP Opinion for LEMTRADA(TM) (alemtuzumab) in Europe
HSMN NewsFeed - 29 Apr 2013
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
UPLYSO(TM) (alfataliglicerase) Approved in Mexico and Chile for the Treatment of Gaucher Disease
HSMN NewsFeed - 28 Feb 2013
FDA Grants QIDP and Fast Track Designations for Cubist’s Late-Stage Antibiotic Candidates
FDA Grants QIDP and Fast Track Designations for Cubist’s Late-Stage Antibiotic Candidates
HSMN NewsFeed - 22 Feb 2013
Lupin Receives FDA Approval for New Drug Application for SUPRAX(R) Oral Suspension, 500 mg/5mL
Lupin Receives FDA Approval for New Drug Application for SUPRAX(R) Oral Suspension, 500 mg/5mL
HSMN NewsFeed - 14 Feb 2013
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
HSMN NewsFeed - 13 Feb 2013
Sobi gains distribution rights for Megace(R), Monopril(R), Cefzil(R); and Duricef(R); from PharmaSwiss
Sobi gains distribution rights for Megace(R), Monopril(R), Cefzil(R); and Duricef(R); from PharmaSwiss
HSMN NewsFeed - 13 Sep 2012
NovaBay's NeutroPhase(R) Used in New Therapeutic Technique for Management of Necrotizing Fasciitis
NovaBay's NeutroPhase(R) Used in New Therapeutic Technique for Management of Necrotizing Fasciitis
HSMN NewsFeed - 14 Nov 2011
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
Genzyme Announces Successful Phase III Results for Alemtuzumab (LEMTRADA(TM*)) in Multiple Sclerosis
HSMN NewsFeed - 14 Oct 2011
NovaBay Pharmaceuticals Spotlights NeutroPhase(R) at the Symposium on Advanced Wound Care (SAWC)
NovaBay Pharmaceuticals Spotlights NeutroPhase(R) at the Symposium on Advanced Wound Care (SAWC)
HSMN NewsFeed - 4 Oct 2011
NovaBay Pharmaceuticals Names David W. Stroman, Ph.D. as Head of Ophthalmic Drug Development
NovaBay Pharmaceuticals Names David W. Stroman, Ph.D. as Head of Ophthalmic Drug Development
HSMN NewsFeed - 28 Sep 2011
NovaBay Pharmaceuticals Names Russell A. Hoon as Vice President of Its Advanced Wound Care Business Unit
NovaBay Pharmaceuticals Names Russell A. Hoon as Vice President of Its Advanced Wound Care Business Unit
HSMN NewsFeed - 15 Sep 2011
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
Acorda Therapeutics Announces Enrique Carrazana, M.D. Joins Company as Chief Medical Officer
HSMN NewsFeed - 25 Jul 2011
TARIS Appoints Christopher Searcy as the Company’s Chief Business Officer
TARIS Appoints Christopher Searcy as the Company’s Chief Business Officer
HSMN NewsFeed - 16 May 2011
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
Biogen Idec Receives Approval for FAMPYRA in Australia to Improve Walking Ability in Adult Patients with MS
HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
HSMN NewsFeed - 11 Apr 2011
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
Avanir Pharmaceuticals Announces Appointment of William Sibold as Chief Commercial Officer
HSMN NewsFeed - 31 Jan 2011
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
AVANIR Pharmaceuticals Announces U.S. Launch and Availability of NUEDEXTA for Pseudobulbar Affect
HSMN NewsFeed - 26 Jul 2010
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
HSMN NewsFeed - 21 Jun 2010
APP Pharmaceuticals Announces Approval and Launch of First Generic Aztreonam for Injection, USP
APP Pharmaceuticals Announces Approval and Launch of First Generic Aztreonam for Injection, USP
HSMN NewsFeed - 28 May 2010
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
HSMN NewsFeed - 5 May 2010
Medline Awarded New Novation Urological Agreement Featuring Innovative CAUTI Prevention Tools
Medline Awarded New Novation Urological Agreement Featuring Innovative CAUTI Prevention Tools
HSMN NewsFeed - 23 Mar 2010
New Device Advances the Treatment of Pediatric Vesicoureteral Reflux (VUR)
New Device Advances the Treatment of Pediatric Vesicoureteral Reflux (VUR)
HSMN NewsFeed - 3 Feb 2010
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
Acorda Therapeutics Announces Pricing and Patient Assistance Programs for AMPYRA (dalfampridine)
HSMN NewsFeed - 6 Jan 2010
Acton Pharmaceuticals, Inc. Announces Completion of $15 Million Series A Financing with Sequoia Capital
Acton Pharmaceuticals, Inc. Announces Completion of $15 Million Series A Financing with Sequoia Capital
HSMN NewsFeed - 6 Oct 2009
SurModics Enters Ophthalmic License and Development Agreement with Roche and Genentech
SurModics Enters Ophthalmic License and Development Agreement with Roche and Genentech
HSMN NewsFeed - 30 Jul 2009
Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion
Second Phase III Study Showed Lucentis Improved Vision in Patients With Retinal Vein Occlusion
HSMN NewsFeed - 31 Oct 2008
Pfizer's TOVIAZ(TM) (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder
Pfizer's TOVIAZ(TM) (fesoterodine fumarate) Receives FDA Approval for the Treatment of Overactive Bladder
HSMN NewsFeed - 5 Sep 2008
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
Elan and Biogen Idec Initiate First Clinical Trial of TYSABRI(R) in Oncology
HSMN NewsFeed - 22 Jul 2008
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
HSMN NewsFeed - 22 Jul 2008
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
Biogen Idec and Elan Celebrate Second Anniversary of TYSABRI(R) for the Treatment of Multiple Sclerosis
HSMN NewsFeed - 7 Jul 2008
Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
Light Sciences Oncology Begins Clinical Trials of Litx Therapy in Patients with Enlarged Prostate
HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
HSMN NewsFeed - 28 Apr 2008
Covalon's Antimicrobial Coating on Foley Catheters Reduces Infections to "Zero" in Six Month Hospital Study
Covalon's Antimicrobial Coating on Foley Catheters Reduces Infections to "Zero" in Six Month Hospital Study
HSMN NewsFeed - 22 Apr 2008
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
HSMN NewsFeed - 15 Apr 2008
Alcon's PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
Alcon's PATANASE(R) Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
HSMN NewsFeed - 24 Mar 2008
Depomed Doses First Patient in New Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
Depomed Doses First Patient in New Phase 3 Clinical Trial of Gabapentin GR in Postherpetic Neuralgia
HSMN NewsFeed - 10 Mar 2008
Symbollon Pharmaceuticals Signs Term Sheet to Acquire Chinese Pharmaceutical Company
Symbollon Pharmaceuticals Signs Term Sheet to Acquire Chinese Pharmaceutical Company
HSMN NewsFeed - 22 Feb 2008
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
Abbott Receives FDA Approval for HUMIRA(R) (Adalimumab) for Polyarticular Juvenile Idiopathic Arthritis
HSMN NewsFeed - 14 Jan 2008
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
FDA Approves TYSABRI(R) for the Treatment of Moderate-to-Severe Crohn's Disease
HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
HSMN NewsFeed - 29 Oct 2007
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
HSMN NewsFeed - 16 Oct 2007
Siemens Medical Solutions Diagnostics and Sysmex America, Inc. Extend Distribution Agreement
Siemens Medical Solutions Diagnostics and Sysmex America, Inc. Extend Distribution Agreement
HSMN NewsFeed - 25 Sep 2007
Depomed and Watson Expand ProQuin(R) XR Promotion Agreement to Include Ob/Gyn Field
Depomed and Watson Expand ProQuin(R) XR Promotion Agreement to Include Ob/Gyn Field
HSMN NewsFeed - 27 Aug 2007
Dr. John Fara Retires as Chairman, President and CEO of Depomed; Mr. Carl Pelzel Appointed President and CEO
Dr. John Fara Retires as Chairman, President and CEO of Depomed; Mr. Carl Pelzel Appointed President and CEO
HSMN NewsFeed - 16 Aug 2007
Covalon Advances its Antimicrobial Coating to be Non-Blood-Clotting for Venous Access Catheters and Devices
Covalon Advances its Antimicrobial Coating to be Non-Blood-Clotting for Venous Access Catheters and Devices
HSMN NewsFeed - 10 Aug 2007
APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection
APP Receives Expedited Approval for the First and Only Generic Cefotetan Disodium for Injection
HSMN NewsFeed - 23 Jul 2007
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
TYSABRI(R) Celebrates One-Year Anniversary as a Treatment for Multiple Sclerosis
HSMN NewsFeed - 10 Jul 2007
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
Depomed Announces Results of Phase 3 Clinical Trial for Gabapentin GR(TM) In Postherpetic Neuralgia
HSMN NewsFeed - 27 Jun 2007
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
Aspreva and Roche announce preliminary results for phase III study evaluating CellCept in lupus nephritis
HSMN NewsFeed - 26 Jun 2007
Advancis Pharmaceutical Reports on Meeting with FDA Reviewing Keflex PULSYS Phase III Trial Design
Advancis Pharmaceutical Reports on Meeting with FDA Reviewing Keflex PULSYS Phase III Trial Design
HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
HSMN NewsFeed - 7 May 2007
Early Results of the CellCept(R) Spare the Nephron Study Examine Kidney Function
Early Results of the CellCept(R) Spare the Nephron Study Examine Kidney Function
HSMN NewsFeed - 18 Apr 2007
Kane Biotech and Harland Medical Systems Announce Commercial License Agreement
Kane Biotech and Harland Medical Systems Announce Commercial License Agreement
HSMN NewsFeed - 11 Apr 2007
Ranbaxy Receives Approval To Market Cefprozil Tablets and Cefprozil Powder For Oral Suspension in Canada
Ranbaxy Receives Approval To Market Cefprozil Tablets and Cefprozil Powder For Oral Suspension in Canada
HSMN NewsFeed - 2 Apr 2007
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
HSMN NewsFeed - 12 Feb 2007
Depomed and Biovail Sign License Agreement for AcuForm(TM) Drug Delivery Technology
Depomed and Biovail Sign License Agreement for AcuForm(TM) Drug Delivery Technology
HSMN NewsFeed - 2 Feb 2007
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
FDA Approves New Dosing Recommendations for RAPAMUNE in High Immunologic Risk Renal Transplant Patients
HSMN NewsFeed - 21 Dec 2006
Depomed Receives $10 Million License Fee from Esprit and Withdraws Arbitration Proceeding
Depomed Receives $10 Million License Fee from Esprit and Withdraws Arbitration Proceeding
HSMN NewsFeed - 18 Dec 2006
Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
Depomed Delivers Notice of Breach and Demand for Arbitration to Esprit Pharma
HSMN NewsFeed - 26 Oct 2006
Aspreva Pharmaceuticals Announces Preliminary Results of Phase III Trial of CellCept for Myasthenia Gravis
Aspreva Pharmaceuticals Announces Preliminary Results of Phase III Trial of CellCept for Myasthenia Gravis
HSMN NewsFeed - 23 Aug 2006
Depomed and King Pharmaceuticals Prepare for Launch of Glumetza(TM) as Timely, New ADA Guidelines Are Issued
Depomed and King Pharmaceuticals Prepare for Launch of Glumetza(TM) as Timely, New ADA Guidelines Are Issued
HSMN NewsFeed - 28 Jun 2006
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
HSMN NewsFeed - 5 Jun 2006
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
FDA Approves the Reintroduction of TYSABRI(R) for the Treatment of Relapsing Forms of Multiple Sclerosis
HSMN NewsFeed - 3 Jun 2006
Serum HER-2/neu Change Predicts Clinical Outcome to Trastuzumab-Based Therapy
Serum HER-2/neu Change Predicts Clinical Outcome to Trastuzumab-Based Therapy
HSMN NewsFeed - 22 May 2006
Medtronic Launches PROSTIVA(TM) RF Therapy System, Proven Treatment Option for Enlarged Prostate
Medtronic Launches PROSTIVA(TM) RF Therapy System, Proven Treatment Option for Enlarged Prostate
HSMN NewsFeed - 15 May 2006
Advancis Pharmaceutical Receives FDA Approval Letter for New Strengths of Keflex
Advancis Pharmaceutical Receives FDA Approval Letter for New Strengths of Keflex
HSMN NewsFeed - 10 May 2006
Depomed Finalizes Phase III Clinical Trial Protocol for Gabapentin GR(TM)
Depomed Finalizes Phase III Clinical Trial Protocol for Gabapentin GR(TM)
HSMN NewsFeed - 29 Mar 2006
Depomed and Madaus S.r.l. Announce Acceptance of the Application for Approval of ProQuin(R) XR in Sweden
Depomed and Madaus S.r.l. Announce Acceptance of the Application for Approval of ProQuin(R) XR in Sweden
HSMN NewsFeed - 24 Mar 2006
NMP22(R) BladderChek(R) Test Detected 100% of Dangerous Tumors in Women at Risk for Bladder Cancer
NMP22(R) BladderChek(R) Test Detected 100% of Dangerous Tumors in Women at Risk for Bladder Cancer
HSMN NewsFeed - 28 Feb 2006
Advancis Pharmaceutical Strengthens Sales and Marketing Capability With Addition of Key Personnel
Advancis Pharmaceutical Strengthens Sales and Marketing Capability With Addition of Key Personnel
Additional items found! 119

Members Archive contains
119 additional stories matching:
urinary tract infection
(Password required)
urinary tract infection
(Password required)